Journal Mobile Options
Table of Contents
Vol. 36, No. 1, 1999
Issue release date: July 1999
Eur Urol 1999;36:1–13
(DOI:10.1159/000019919)

A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

Djavan B. · Marberger M.
Department of Urology, University of Vienna, Austria

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To assess whether the α1-adrenoceptor antagonists currently available for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) (alfuzosin, terazosin, doxazosin and tamsulosin) can be distinguished with regard to clinical efficacy and/or tolerability. Methods: Up-to-date analysis of clinical placebo-controlled or direct comparative studies with α1-adrenoceptor antagonists in patients with LUTS suggestive of BPO derived from a MEDLINE search in October 1998. All retrieved studies were analyzed with regard to efficacy and tolerability. Efficacy was evaluated by the percentage improvement in total symptom score and Qmax (mean end of study value relative to mean baseline value). Tolerability was evaluated by means of study withdrawal rate because of adverse events and the incidence of vasodilatatory adverse events (e.g. dizziness and orthostatic hypotension). Results: Indirect comparison of data derived from the placebo-controlled studies involving 6,333 patients and the data derived from the direct comparative studies involving 507 patients demonstrate that all α1-adrenoceptor antagonists (alfuzosin, terazosin, doxazosin and tamsulosin) produce comparable improvements in LUTS and urinary flow. Total symptom score is in general improved by 30–40% and Qmax by 16–25%. The difference between currently available α1-adrenoceptor antagonists is related to their side effect profile. Alfuzosin (especially the sustained release formulation) and tamsulosin (modified release formulation 0.4 mg) seem to be better tolerated than terazosin and doxazosin. The percentage of patients that withdrew due to bothersome side effects with alfuzosin and tamsulosin 0.4 mg was comparable to that with placebo (about 4–10%) whereas in the terazosin and doxazosin studies an additional 4–10% of patients dropped out because they did not tolerate the therapy. Tamsulosin has less effect on blood pressure than alfuzosin (especially in elderly patients) and causes less symptomatic orthostatic hypotension during orthostatic stress testing than terazosin. Conclusions: All α1-adrenoceptor antagonists seem to have similar efficacy in improving symptoms and flow. The difference between α1-adrenoceptor antagonists is related to their side effect profile. Alfuzosin and tamsulosin appear to be better tolerated than doxazosin, terazosin and prazosin.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
  2. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
  3. Abrams P: Managing lower urinary tract symptoms in older men. Br Med J 1995;310:1113–1117.
  4. Denis L, McConnell J, Yoshida O, Khoury S, Abrams P, Barry M, Bartsch G, Cockett A, Corriere J, Dreikorn K, Gibbons R, Griffiths K, Hald T, Holtgrewe L, Jardin A, Koyanagi T, Mebust W, Murphy G, Roehrborn C, Smith P, Members of the Committees: 4th International Consultation on BPH. Recommendations of the International Scientific Committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction; in Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O (eds): Proc 4th Int Consultation on Benign Prostatic Hyperplasia (BPH), Paris, July 2–5, 1997. Plymouth, Plymbridge Distributers Ltd., 1998, pp 669–684.
  5. Peters DH, Sorkin EM: Finasteride: A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993;46:177–208.
  6. Caine M: Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:641–649.
  7. Chapple CR: α-Adrenergic blocking drugs in bladder outflow obstruction: What potential has α1-adrenoceptor selectivity? Br J Urol 1995;76(suppl 1):47–55.
  8. Kunisawa Y, Kawabe K, Niijima T, Honda K, Takenaka T: A pharmacological study of alpha-adrenergic receptor subtypes in smooth muscle of human urinary bladder and prostatic urethra. J Urol 1985;134:396–398.
  9. Yamada S, Tanaka C, Kimura R, Kawabe K: Alpha-1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha-1-antagonists. Life Sci 1994;54:1845–1854.
  10. Andersson KE: Uroselectivity; in Cockett AT, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds): Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Scientific Communications International, 1996, pp 541–542.
  11. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201–207.
  12. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA: Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned α1-adrenergic receptor subtypes. Prostate 1997;33:55–59.
  13. Michel MC, Grübbel B, Taguchi K, Verfürth F, Otto T, Kröpfl D: Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned alpha-1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996;16:21–28.

    External Resources

  14. Kenny BA, Naylor AM, Carter AJ, Read AM, Greengrass PM, Wyllie MG: Effect of α1-adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 1994;44:52–57.
  15. Sudoh K, Tanaka H, Inagaki O, Asano M, Takenaka T: Effect of tamsulosin, a novel α1-adrenoceptor antagonist, on urethral pressure profile in anaesthetized dogs. J Auton Pharmacol 1996;16:147–154.
  16. Brune ME, Katwala SP, Milicic I, Buckner SA, Ireland LM, Kerwin JF, Hancock AA: Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. Pharmacology 1996;53:356–368.
  17. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 1997;282:228–235.
  18. Harada K, Ohmori M, Fujimura A: Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular α1-adrenoceptors in humans. Arch Pharmacol 1996;354:557–561.

    External Resources

  19. Schäfers RF, Fokuhl B, Wasmuth A, Schumacher H, de Mey C, Philipp T, Michel MC: Differential inhibition of phenylephrine-induced blood pressure elevations by the α1adrenoceptor antagonists, tamsulosin and terazosin. Br J Clin Pharmacol 1998; in press.
  20. Eri LM, Tveter KJ: α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995;154:923–934.
  21. Chapple CR: Pharmacotherapy for benign prostatic hyperplasia: The potential for α1-adrenoceptor subtype-specific blockade. Br J Urol 1998;81(suppl 1):34–47.
  22. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991;337:1457–1461.
  23. Hansen BJ, Nordling J, Mensink HJA, Walter S, Meyhoff H-H, ALFECH Study Group: Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1994;157(suppl):169–176.
  24. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, ALGEBI Study Group: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997;31:190–198.
  25. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467–1474.
  26. Di Silverio F: Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. Br J Urol 1992;70(suppl 1):22–26.
  27. Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV, Kirk D: Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 1992;70(suppl 1):17–21.
  28. Brawer MK, Adams G, Epstein H, Terazosin Benign Prostatic Hyperplasia Study Group: Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993;2:929–935.
  29. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, Padley RJ, for the HYCAT Investigator Group: The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996;47:159–168.

    External Resources

  30. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533–539.
  31. Elhilali MM, Ramsey EW, Barkin J, Casey RW, Boake RC, Beland G, Fradet Y, Trachtenberg J, Orovan WL, Schick E, Klotz LH: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996;47:335–342.

    External Resources

  32. Christensen MM, Holme JB, Rasmussen PC, Jacobsen F, Nielsen J, Nørgaard JP, Olesen S, Noer I, Wolf H, Husted SE: Doxazosin treatment in patients with prostatic obstruction: A double-blind placebo-controlled study. Scand J Urol Nephrol 1993;27:39–44.
  33. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N, for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 1995;154:105–109.

    External Resources

  34. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N, for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995;154:110–115.
  35. Mobley DF, Kaplan S, Ice K, Gaffney M, Dias N: Effect of doxazosin on the symptoms of benign prostatic hyperplasia: Results from three double-blind placebo-controlled studies. Int J Clin Pract 1997;51:282–288.
  36. Roehrborn CG, Siegel RL: Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. Urology 1996;48:406–415.
  37. Janknegt RA, Chapple CR, for the Doxazosin Study Groups: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993;24:319–326.
  38. Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:587–596.

    External Resources

  39. Abrams P, Schulman CC, Vaage S, and the European Tamsulosin Study Group: Tamsulosin, a selective α1C-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br J Urol 1995;76:325–336.

    External Resources

  40. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AFGVM, Abrams P, on behalf of the European Tamsulosin Study Group: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155–167.

    External Resources

  41. Lepor H for the Tamsulosin Investigator Group: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892–900.
  42. Lepor H for the Tamsulosin Investigator Group: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Urology 1998;51:901–906.
  43. Buzelin JM, Hebert M, Blondin P, and the PRAZALF Group: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993;72:922–927.
  44. Buzelin JM, Fonteyne E, Kontturi M, Witjes WPJ, Khan A, for the European Tamsulosin Study Group: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597–605.

    External Resources

  45. Lee E, Lee C: Clinical comparison of selective and non-selective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606–611.

    External Resources

  46. De Mey C, Michel MC, McEwen J, Moreland T: A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481–488.
  47. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, and the BPHALF Group: Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12–18 month assessment. Br J Urol 1993;72:615–620.
  48. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, and the BPHALF Group: Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 24–30 month survey. Br J Urol 1994;74:579–584.
  49. Lepor H, for the Terazosin Research Group: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995;45:406–413.

    External Resources

  50. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N, for the Multicenter Study Group: Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997;157:525–530.
  51. Schulman CC, Cortvriend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: analysis of a multinational multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:145–154.

    External Resources

  52. Schulman CC, Lock TMTW, Buzelin JM: Tamsulosin: 3-year follow-up of efficacy & safety in 516 patients with LUTS suggestive of BPO. J Urol 1998;159(5 suppl):256(abstr 983).
  53. Lepor H, and the Tamsulosin Investigator Group: Tamsulosin, long-term, open-label, extension study to evaluate response and efficacy. J Urol 1997;157(4 suppl):331(abstr 1293).
  54. Djavan B, Shariat S, Schäfer B, Marberger M: Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol 1998;160:772–776.
  55. Djavan B, Larson TR, Blute ML, Marberger M: Transurethral microwave thermotherapy: What role should it play versus medical management in the treatment of benign prostatic hyperplasia? Urology 1999;52:935–947.
  56. Djavan B, Roehrborn C, Shariat S, Ghawidel K, Marberger M: Prospective, randomized comparison of high-energy transurethral microwave therapy versus α-blocker treatment in patients with benign prostatic hyperplasia. J Urol 1999;161:139–143.
  57. Djavan B, Shariat S, Fakhari M, Ghawidel K, Seitz C, Partin AW, Roehrborn CG, Marberger M: Neoadjuvant and adjuvant alpha-blockade improves early results of high energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: A randomized, prospective clinical trial. Urology 1999;53:251–259.
  58. Coffey DS: Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol 1998;81(suppl 1):1–5.
  59. Kaplan SA, D’Alisera PM: Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J Geront 1998;53A(3):M201–M206.
  60. Wilde MI, Fitton A, McTavish D: Alfuzosin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410–429.
  61. Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C: Safety profile of 3 months’ therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996;29:29–35.
  62. Chapple CR, Baert L, Thind P, Höfner K, Khoe GS, Spångberg A, on behalf of the European Tamsulosin Study Group: Tamsulosin 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). Eur Urol 1997;32:462–470.

    External Resources

  63. Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M: Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability? J Urol 1998;160:784–791.

    External Resources

  64. Lowe FC: Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect. Clin Ther 1997;19:730–742.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50